Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPY2R | P49146 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4401474 | 0.84 | MAPT (0.45) | MAPTOPRM1ACHESIGMAR1TMEM97 | |
| SCHEMBL28711007 | 0.81 | MAPT (0.45) | MAPTACHESIGMAR1TMEM97 | |
| SCHEMBL21057421 | 0.81 | MAPT (0.45) | MAPTACHESIGMAR1TMEM97 | |
| SCHEMBL4395795 | 0.81 | MAPT (0.42) | MAPTOPRM1DRD4SIGMAR1TMEM97 | |
| SCHEMBL4396042 | 0.77 | SIGMAR1 (0.41) | MAPTOPRM1DRD4SIGMAR1 | |
| SCHEMBL11949296 | 0.77 | LMNA (0.44) | MAPTOPRM1ACHESIGMAR1 | |
| SCHEMBL4401549 | 0.73 | HRH2 (0.51) | SIGMAR1 | |
| SCHEMBL20588229 | 0.73 | ACHE (0.56) | MAPTACHESIGMAR1 | |
| SCHEMBL6853255 | 0.73 | ACHE (0.56) | MAPTACHESIGMAR1 | |
| SCHEMBL4391091 | 0.72 | CYP3A4 (0.41) | MAPTOPRM1HTTOPRL1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190854-A1 | Hydroamination of Alkenes | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190854-A1 | Hydroamination of Alkenes | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190854-A1 | Hydroamination of Alkenes | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-07-26 | — | — | US | disclosed |
| US-8188302-B2 | Hydroamination of alkenes | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188302-B2 | Hydroamination of alkenes | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188302-B2 | Hydroamination of alkenes | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090156824-A1 | Hydroamination of Alkenes | BOARD OF TRUSTEES OF UNIVERSITY OF ILLINOIS (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156824-A1 | Hydroamination of Alkenes | BOARD OF TRUSTEES OF UNIVERSITY OF ILLINOIS (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156824-A1 | Hydroamination of Alkenes | BOARD OF TRUSTEES OF UNIVERSITY OF ILLINOIS (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156824-A1 | Hydroamination of Alkenes | HRH3, HRH4, H1-3 | MAPT 3666/4885OPRM1 465/4885DRD4 272/4885 |
| US-20120190854-A1 | Hydroamination of Alkenes | HRH3, HRH4, H1-3 | MAPT 3666/4885OPRM1 465/4885DRD4 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.